Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | CPA1 | P15085 | 2/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | GRN | P28799 | 2/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | GFRA3 | O60609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3902883 | 0.85 | MME (0.56) | GPR132POLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16115188 | 0.79 | POLB (0.69) | POLBALDH1A1MMECNR2CTSS | |
| SCHEMBL16114852 | 0.79 | POLB (0.69) | POLBALDH1A1MMECNR2CTSS | |
| SCHEMBL3906969 | 0.79 | USP2 (0.53) | GPR132POLBALDH1A1SMN1; SMN2CNR2 | |
| SCHEMBL5047012 | 0.79 | GPR132 (0.43) | GPR132POLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4065339 | 0.79 | SHMT1 (0.48) | GPR132POLBCNR2 | |
| SCHEMBL5041103 | 0.78 | MME (0.43) | GPR132POLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5046992 | 0.77 | GPR132 (0.42) | GPR132POLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5041097 | 0.77 | MME (0.42) | GPR132POLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4064892 | 0.77 | CTBP2 (0.54) | GPR132POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653952-A4 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2007-04-04 | — | — | EP | claimed |
| US-7112599-B2 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2006-09-26 | — | — | US | claimed |
| EP-1653952-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005016267-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050032859-A1 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2005-02-10 | — | — | US | claimed |
| EP-1653952-A4 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7112599-B2 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1653952-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016267-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050032859-A1 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032859-A1 | Oxazole compounds for the treatment of neurodegenerative disorders | APP, OXA1L, BACE1 | GPR132 669/4885POLB 3353/4885ALDH1A1 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.